Is Boswellia the same as frankincense?

Broadly, yes. "Frankincense" is the common trade name for the dried resin of various Boswellia species, most historically B. sacra from the Arabian Peninsula and East Africa. B. serrata — the species most studied in contemporary supplement research — is sometimes called Indian frankincense or Indian olibanum to distinguish it. The chemistry differs between species, so these aren't interchangeable in a research context even if they're sold under similar labels.

How is Boswellia regulated in Australia?

Boswellia extract products are typically listed on the Australian Register of Therapeutic Goods (ARTG) as complementary medicines. The TGA assesses listed medicines for safety and quality, but not efficacy in the way registered medicines are assessed. Products must comply with Good Manufacturing Practice (GMP) standards. Boswellia is not scheduled under the Poisons Standard and does not carry the import restrictions that apply to, for example, kava.

Does Boswellia have poor bioavailability?

Boswellic acids, especially AKBA, are lipophilic compounds that are not well absorbed in their unformulated state and undergo significant first-pass metabolism in the liver. Some extract preparations use phospholipid complexes or other formulation strategies to improve absorption. The research evidence on how well these strategies work in practice — and whether improved plasma levels translate to any meaningful effect — is still being worked through.

Can Boswellia products make health claims on their labels in Australia?

Only within the limits set by the TGA's permitted indications framework for listed complementary medicines. Listed medicines can carry low-level, general indications — such as general support for joint health — but are prohibited from making claims relating to serious diseases. The TGA does not assess the efficacy of listed medicines before they go to market, so a listing number on a product label is not an endorsement of any claimed effect.

Boswellia: Traditional Use, Constituents and Evidence

By Naomi Ellison · 29 April 2026 · 10 min read

A small lump of resin burned on a quiet Sunday is a very old habit. Frankincense has been lit in homes and temples for roughly five thousand years, and the plant behind it is only now getting the kind of laboratory attention its long traditional use might suggest it deserved.

Boswellia, the genus behind frankincense, is one of those plants that keeps rewarding scrutiny. Its resin has been traded across the Arabian Peninsula, East Africa and the Indian subcontinent since at least the early Bronze Age. Today it sits in a fascinating position: widely sold as a complementary medicine supplement, subject to a genuine and growing body of pharmacological research, and still carrying more questions than answers. Let's go through it carefully.

What is Boswellia, and where does it come from?

The genus Boswellia belongs to the family Burseraceae and comprises around 25 species of trees and shrubs, mostly native to the dry, rocky regions of the Horn of Africa, the Arabian Peninsula and the Indian subcontinent. The two species that appear most often in contemporary research and supplement formulations are Boswellia serrata (Indian frankincense, sometimes called Indian olibanum) and Boswellia sacra (the Omani and Yemeni species historically prized in the ancient incense trade). General background on the genus is available in the Wikipedia entry on Boswellia.

Species matter more than the common name suggests. "Frankincense" is a trade term covering resins from several trees, and the chemistry differs between species, between regions and even between harvests. That is one reason a research finding on one resin cannot simply be carried over to another.

The resin is obtained by making incisions in the bark. The tree "bleeds" a milky-white exudate that hardens on exposure to air into the teardrop-shaped lumps you'll find in any good spice market. Harvesting is labour-intensive and, in recent decades, has raised genuine conservation concerns. A 2019 study in Nature Sustainability modelled population dynamics across sub-Saharan Africa and projected significant long-term decline under current harvesting pressure, something the broader herbal industry has been too slow to take seriously, in my view.

Traditional use across cultures

In Ayurvedic medicine, Boswellia serrata resin, known as shallaki, appears in classical texts including the Charaka Samhita and Sushruta Samhita, where it is described in formulations applied to conditions involving the joints, the digestive system, and the respiratory tract. This is a descriptive, historical observation; the texts predate controlled clinical methodology by roughly two millennia.

In traditional Somali and Ethiopian medicine, Boswellia species have been used topically and as fumigants. The ancient Egyptians used the resin in cosmetics, embalming preparations and ritual. Ancient Greek and Roman physicians, Dioscorides among them, referenced olibanum in pharmacopoeial texts.

The common thread across these traditions is that the resin was rarely used as a simple single-compound extract; it was prepared in combination with other botanicals, carriers, and processing steps that would have altered its chemistry considerably. This matters when evaluating modern research, which typically isolates specific fractions.

A fair reading of this history is modest. Long use tells us a plant was valued, available and culturally meaningful. It does not tell us that any particular effect occurred, because traditional records were never designed to separate a plant's action from expectation, ritual or the natural course of an ailment. Readers comparing how different traditional botanicals are described might also look at our entries on turmeric and curcumin and ginger, which raise many of the same questions about historical record versus modern evidence.

Key chemical constituents

The pharmacologically interesting components of Boswellia resin are the boswellic acids, a family of pentacyclic triterpenic acids. The main ones studied are:

β-boswellic acid (BA), the most abundant, though not considered the most pharmacologically active in isolation
Acetyl-11-keto-β-boswellic acid (AKBA), the compound that has attracted the most research attention, present in relatively small quantities in raw resin
11-keto-β-boswellic acid (KBA)
Acetyl-β-boswellic acid

AKBA has been the focus of considerable in vitro and animal research because of its interaction with 5-lipoxygenase (5-LOX), an enzyme involved in the synthesis of leukotrienes, signalling molecules in the arachidonic acid cascade. This is a mechanistic observation about enzyme chemistry, not a statement that the compound treats any disease state in humans.

The phrase "in vitro" is worth unpacking. It means the work was done in a dish or test tube, usually on isolated enzymes or cells. Such experiments are useful for generating hypotheses, but a compound that acts on an enzyme in a dish may behave very differently once it has to be absorbed, circulated and distributed through a living body.

Beyond boswellic acids, the resin contains volatile terpenes that contribute to its characteristic scent profile. Among these are alpha-pinene and beta-pinene, both of which appear across many aromatic plant species and have their own pharmacological literature. There are also small amounts of limonene and, depending on the species and growing conditions, traces of linalool. If you've read anything on the terpene profiles of other botanical resins on this site, the overlap will look familiar. Our entry on lavender covers linalool in a plant where it is far more prominent.

Why bioavailability complicates Boswellia supplements

One aspect of Boswellia chemistry that complicates supplement formulations is bioavailability. Boswellic acids, particularly AKBA, are poorly absorbed in their unformulated state. They are highly lipophilic and subject to significant first-pass metabolism. Some commercial extract preparations use phospholipid complexes or other delivery systems to address this; the research literature on whether these strategies translate to meaningfully higher plasma levels is mixed.

In plain terms, lipophilic means fat-loving: the molecules dissolve in fats far more readily than in water, which makes them awkward to absorb from a watery gut environment. First-pass metabolism describes the way compounds absorbed from the gut pass through the liver before reaching the wider circulation, where a portion may be chemically altered or cleared. Both effects can mean that the amount of a compound swallowed is a poor guide to the amount that actually reaches tissues.

The takeaway is not that formulation technology is pointless. It is that "enhanced absorption" is a hypothesis each product has to support with its own data, and a delivery claim based on a different preparation says very little about the one in your hand.

What the research shows, and where it stops

The clinical research on Boswellia extracts is more substantial than for many plant-based supplements, but it carries real methodological limitations that deserve honest discussion. The strongest research signal comes from areas involving the 5-LOX pathway and leukotriene synthesis, studied in the context of conditions characterised by inflammatory activity.

A number of randomised controlled trials have been published examining B. serrata extract in osteoarthritis, asthma and inflammatory bowel conditions. A 2011 systematic review published in Phytomedicine (Urban & Fischer) found some positive signals in osteoarthritis trials but noted small sample sizes, short durations, and heterogeneity in extract quality and dosing as significant confounders. Those limitations haven't been fully resolved in the decade since.

The honest position is this: the mechanistic rationale is plausible, there is preliminary human trial data in specific contexts, but there is no robust, large-scale, independently replicated trial evidence that meets the evidentiary standard we'd apply to a conventional pharmaceutical. Anyone presenting the Boswellia literature as settled science is getting ahead of themselves.

From a pharmacokinetics standpoint (see our pharmacokinetics glossary entry), even well-designed trials face the challenge that plasma levels of boswellic acids vary substantially between individuals and between extract preparations. A standardised extract with a declared AKBA content is not the same thing as confirmed bioavailability at a target tissue.

How to read claims about Boswellia research

A systematic review pools and appraises many trials, which is why it carries more weight than a single study. But a review is only as good as the trials inside it. When those trials use different extracts, different amounts and different outcome measures, combining them is a bit like averaging recipes that share only a name. Heterogeneity of that kind is exactly what the 2011 review flagged.

Several questions are worth asking of any Boswellia claim. Which species and which extract were tested? Was the trial randomised and blinded, and who funded it? How many participants took part, and for how long? Was the result replicated by an independent group? A confident headline that cannot answer these is marketing, not evidence. If you want to see how the same scrutiny applies to other well-known botanicals, our entries on ginkgo biloba and licorice root take a similar approach.

I'd also argue that "standardised to AKBA" has become a slightly overworked selling point. It tells you a marker compound was measured, which is a quality control step. It does not tell you the marker is the one that matters, or that the product has been studied in people.

Australian regulatory context

In Australia, Boswellia products are typically listed on the Australian Register of Therapeutic Goods (ARTG) as complementary medicines, specifically as Listed medicines under the ARTG framework administered by the Therapeutic Goods Administration (TGA). You can find our overview of the ARTG and what listing versus registration means in terms of evidence assessment.

Listed complementary medicines in Australia are assessed for safety and quality, but not for efficacy in the way that registered medicines are. This means a product can carry an ARTG listing number without the TGA having evaluated whether it actually does what the label implies. The TGA's permitted indications framework sets boundaries on what health claims can appear on the label, and claims linked to serious diseases are prohibited. Boswellia products would typically carry general, low-level indications such as "support for healthy joint function" rather than disease-specific claims.

Manufacturers supplying listed Boswellia products in Australia must comply with Good Manufacturing Practice (GMP) standards, which govern consistency, contamination controls and labelling accuracy. This doesn't guarantee a product works; it guarantees certain quality standards in how it was made.

There are no scheduling restrictions on Boswellia resin or its extracts under the Poisons Standard; it is not a Schedule 4 or Schedule 8 substance. Unlike kava, which carries specific import controls under Australian border law (the Customs (Prohibited Imports) Regulations 1956 restrict the commercial importation of kava products beyond personal use quantities), Boswellia has no equivalent restriction. It can be imported and sold commercially subject to the usual TGA and biosecurity requirements.

Worth mentioning: the TGA has been actively reviewing the evidence standards for listed complementary medicines in recent years, with ongoing reform proposals that could raise the bar for permitted indications. Anyone formulating or selling in this category should be watching those developments.

Boswellia and the cannabinoid-adjacent research

One relatively recent thread in the Boswellia literature interests me specifically because of how much of my reading sits close to cannabinoid science. Some research groups have investigated whether boswellic acids interact with components of the endocannabinoid system. Preliminary in vitro work has suggested possible activity at CB2 receptors, the receptor subtype expressed particularly in immune cells and peripheral tissues; though this research is early-stage and has not been replicated at the scale needed to draw firm conclusions.

The reason this is worth noting, rather than quietly ignoring, is that it speaks to a broader pattern in phytomedicine research: bioactive compounds from traditional plant medicines are sometimes found to engage receptor systems that weren't even described until the late 20th century. It's a reminder that the pharmacological story for many well-used plants is genuinely incomplete. See our phytomedicine overview for more on this framing.

Equally, an early receptor-binding result is a long way from a demonstrated effect in people. It is a prompt for better questions, and the sensible response is curiosity paired with patience. For further reading on the plant itself, the Wikipedia entry on frankincense gives a useful general overview of the resin and its trade.

Sources

Naomi Ellison, Botanical & phytomedicine writer

Common questions

Is Boswellia the same as frankincense?: Broadly, yes. "Frankincense" is the common trade name for the dried resin of various Boswellia species, most historically B. sacra from the Arabian Peninsula and East Africa. B. serrata — the species most studied in contemporary supplement research — is sometimes called Indian frankincense or Indian olibanum to distinguish it. The chemistry differs between species, so these aren't interchangeable in a research context even if they're sold under similar labels.
How is Boswellia regulated in Australia?: Boswellia extract products are typically listed on the Australian Register of Therapeutic Goods (ARTG) as complementary medicines. The TGA assesses listed medicines for safety and quality, but not efficacy in the way registered medicines are assessed. Products must comply with Good Manufacturing Practice (GMP) standards. Boswellia is not scheduled under the Poisons Standard and does not carry the import restrictions that apply to, for example, kava.
What are boswellic acids and why do researchers focus on them?: Boswellic acids are a family of pentacyclic triterpenic acids found in Boswellia resin. The most studied is acetyl-11-keto-β-boswellic acid (AKBA), which has been investigated for its interaction with 5-lipoxygenase (5-LOX), an enzyme involved in leukotriene synthesis. This is a mechanistic observation about biochemistry — it does not constitute evidence that products containing AKBA treat any condition in humans.
Does Boswellia have poor bioavailability?: Boswellic acids, especially AKBA, are lipophilic compounds that are not well absorbed in their unformulated state and undergo significant first-pass metabolism in the liver. Some extract preparations use phospholipid complexes or other formulation strategies to improve absorption. The research evidence on how well these strategies work in practice — and whether improved plasma levels translate to any meaningful effect — is still being worked through.
Can Boswellia products make health claims on their labels in Australia?: Only within the limits set by the TGA's permitted indications framework for listed complementary medicines. Listed medicines can carry low-level, general indications — such as general support for joint health — but are prohibited from making claims relating to serious diseases. The TGA does not assess the efficacy of listed medicines before they go to market, so a listing number on a product label is not an endorsement of any claimed effect.